NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
26 sept. 2023 07h00 HE
|
NMD Pharma
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26 September 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small...
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
26 sept. 2023 01h00 HE
|
NMD Pharma
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26 September 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small...
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association
08 sept. 2023 07h00 HE
|
NMD Pharma
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association NMD Pharma to host a satellite symposium* at the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
20 juin 2023 07h00 HE
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
20 juin 2023 01h00 HE
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
01 juin 2023 07h00 HE
|
NMD Pharma
Daniel Brennan brings over 25 years of strategic commercial experience leading public and private rare disease and CNS biopharma companies Aarhus, Denmark, 1 June 2023 – NMD Pharma A/S, a...
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
23 mai 2023 07h00 HE
|
NMD Pharma
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion...
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
23 mai 2023 01h00 HE
|
NMD Pharma
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03 janv. 2023 07h00 HE
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03 janv. 2023 01h00 HE
|
NMD Pharma
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...